Dr. Min Wang

Dr. Wang received her Medical degree and Master of Science degree from the Third PRC Medical University in China.  She has completed her Ph.D. from the University of Toronto, Canada in 1994. After a short post-doctoral fellowship with a Canadian Medical Research Council postdoctoral fellowship, she accepted an industry position at Canadian Dimethied Pharmaceutical Research Incorporation managing anti-arthritis drug development.  In 1999, Dr. Wang joined the Parke-Davis pharmaceutical division of Warner Lambert Corp. as a medical scientist and project manager in cardiovascular clinical research and was responsible for the international development of Lipitor and other cardiovascular drugs.  Dr. Wang accepted the position of Associate Director of Cardiovascular and Metabolic Diseases at Bayer Pharmaceutical Inc. in mid 2000. In this role, she manages phase I to IV clinical trials in the global and North America settings, participates in global and local regulatory submissions, and works closely with the teams of Scientific Affairs, Marketing and Sales force. Her focuses in the drug development are in the areas of cardiovascular, diabetes, anti-thrombosis and oncology.  Recently Dr. Wang is promoted as Director and Global Medical Expert of Bayer Global Clinical Development in Asia Pacific and relocated to Beijing of China. 

Dr. Zhengquan (David) He (david.he@ccbpa.com)

Dr. He is the founder and president of Molcan Corporation of Canada, co-founder and vice chairman of Molcan Biopharma of China. Dr. He received his MSc (1985) in Pharmacy from Sichuan University (formerly "West China University of Medical Sciences") , PhD (1990) in Chemistry from University of New Brunswick, worked as Postdoctoral Fellow at University of Toronto. He has held various positions within the pharmaceutical industry and government including deputy director at the Ministry of Health (China), R&D manager at Apotex (the largest pharma company in Canada), board director at BT Pharma (a major joint venture between Apotex and Chinese partner), Carry Biotech & Hengda Pharma etc. Dr. He won “Innovation Award�from Overseas Chinese Federation in 2007, is advisor to the City of Chengdu, China.

Dr. Qinwei Shi (qinwei.shi@ccbpa.com)

Dr. Shi graduated from Shanxi Medical University in 1983, worked as a visiting scholar at the Hospital of Sick Children, Toronto, Ontario during 1985-1987. He obtained Ph.D. in 1992 from the Department of Clinical Chemistry, University of Toronto, and completed postdoctoral training in Genetics Department at the Hospital for Sick Children in 1994. He then joined Spectral Diagnostics Inc. and held positions sequentially as Manager of Molecular Biology Department, Manager of Protein Engineering and Director of Research. He co-founded ZBx Corporation in 2002 where he holds positions of Executive Vice President & Director of Research and Development. Dr. Shi is inventor or co-inventor of 15 US and international patents and sole inventor of ZBx's one-step one-drop rapid diagnostic test system.

Dr. Xuefeng Yu (xuefeng.yu@ccbpa.com)

Dr Yu received his BSc and MSc from Nankai University in China. He obtained his PhD from McGill University in 1997. Dr Yu has more than 15 years of Biotech industrial experiences. From 1996 to 1998, Dr. Yu worked for IBEX Technologies inc. in Montreal as a research scientist. In this role, he was responsible for therapeutic enzymes products development. Dr. Yu joined sanofi pasteur, one of world largest vaccine manufacture in 1998. Since 2001 he has held director and corporate platform leader position in Process Development Department. In this role, he is responsible for bacterial vaccine upstream process development locally and coordination of global activities across three R&D sites. He has played key roles in multiple new vaccines process development, GMP production as well as regulatory submission. Dr. Yu also has played leadership role in new GMP facility validation and technology transfer. Since 2004 Dr. Yu has served as Sanofi Pasteur’s Representative to “Cell-Factory Bioprocessing Networkï¿?(Cell-Net), a nation wide research network funded by Natural Sciences and  Engineering Research Council (NESRC) and industrial partners.

Dr.Wan Jiang (wan.jiang@ccbpa.com)

Dr. Jiang obtained her B.Sc. and M.Sc. from Huazhong Normal University in China and received her Ph.D in Organic Chemistry from Iowa State University in U.S.A. She was a post-doctor at Locker Carbohydrate Institute of University of Southern California U.S.A. and a research associate at Chemistry Department of University of Toronto, Canada. Dr. Jiang has been working at pharmaceutical industrial since 1990, her working experience included research scientist, analytical development supervisor, analytical laboratory manager and director of analytical operations. Presently Dr.Jiang is Director of Product Development-Liquid Dose at Apotex Inc, a largest pharmaceutical company in Canada. Dr.Jiang has intensive knowledge and first-hand experience in various areas of pharmaceutics, such as DMF of active pharmaceutical ingredient, preformulation, formulation development, analytical development, scale-up, manufacture, stability program, submission, approval and product launch. Dr.Jiang is familiar with cGMP requirement, Quality by Design (QbD) and has participated multiple FDA cGMP and PAI inspections. 

Ms. Jianying Wang (jianying.wang@ccbpa.com)

Ms. Wang, born in China, received BSc in Chemical Engineering from South China University of Technology and MBA from Edinburgh Business School in UK. She worked in environmental protection field in China and Canada. Since 1990, she has been working at Novopharm Ltd., a subsidiary of Teva Pharmaceutical Industries Ltd (the largest generic company in the world), as senior biochemist, RA associate, team leader and manager of Regulatory Affairs, and she is now responsible for US submission.

 Dr. Wanren Li (wanren.li@ccbpa.com)

Wanren Li received a B.S. in chemistry from Zhongshan University in 1982.  He worked for the PCB center at North China Institute of Computing Technology in Beijing for seven years. In 1992, he earned his M.S. in Chemistry from University of Montreal.  He moved to University of Quebec (INRS Energy and Materials) for a Ph.D. program in 1993. Wanren joined Apotex Inc. as a research chemist in 1995.  Presently he works for Medicinal Chemistry Department as a scientist. His expertise is in synthesis and property studies of small molecules for the new drug development.  He has extensive experience in organic synthesis and API scale up; analytical research of drug-like properties, STN online.

Dr.Minglong Zhang (minglong.zhang@ccbpa.com)

Dr. Zhang is a Manager in Bill Beauty & Health Product Ltd.   Previously He worked in Apotex, Patheon, Novartis Canada and other Pharmaceutical Companies. He received his Ph.D. from School of Pharmaceutical Sciences at Peking University and M.S. from Institute of Materia Medica, Peking Union Medical College & Chinese Academy of Medical Sciences. He graduated from School of Pharmaceutical Engineering, Shenyang Pharmaceutical University in 1985. He has more than 20 year’s experiences of innovative medicine synthesis, formulation development and process validation as well as analytical method development and validation. He has extensive knowledge of cGMP, FDA, USP, ICH, CP and is familiar with both North American and Chinese pharmaceutical industry processes.

Mr. Haiqi Zhang (haiqi.zhang@ccbpa.com)

Mr. Zhang, graduated from school of information science, Northeast Normal University, had been worked as a librarian, associate research librarian, head of library, in National Institute for Control of Pharmaceutical and Biological Products. During the working years, Haiqi had been participating in the project of national drug information network from Ministry of Health, and setting up the national biological product documentation database. As a visiting scholar, Haiqi had been working on biomedical information disseminating, drug information searching and analysis in the information center, Jikei University School of Medicine, Japan. The research topics, such as Scientometric study on research performance in China; Scientific research collaboration in China; More authors, more institutions and more funding sources: hot papers in biology from 1991 to 1993; Research performance in key medical universities in China observed from the scientific productivity, were published in international information science journals. After coming to Canada, Haiqi has been working in SGS Life Science Laboratory, Canada, and set up Pioneer Biomedical and Pharmaceutical Technology Research Corporation. The company is dedicated to the creative development of consulting services and solutions to the biomedical and pharmaceutical industrial between Canada and China.

Dr. Xinli (Annie) Zhu (annie.zhu@ccbpa.com)

Dr. Zhu received her Medical degree from Hunan Medical University in China and Ph.D. in Biochemistry from the University of Manchester, UK. She worked as Postdoctoral Fellow at the University of Toronto and Mount Sinai Hospital. She subsequently held positions as Manager of Reagent Manufacturing at Spectral Diagnostics and QC Analytical Supervisor at Purdue Pharma. Her current position is Product Validation Specialist at NOVX Systems responsible for product transfer from R & D to Manufacturing and QC.

Dr. Andrew Wu (andrew.wu@ccbpa.com)

Dr. Wu got his PhD in Biosensors & Bioelectrics from the Hong Kong University of Science and Technology. After graduation he moved to University of Toronto as a Post-Doc in 1997. After one-year research in computer image process, Dr. Wu moved to applied information technology industry from academy. The primary focus of Dr. Wu's career is in the e-Commerce architecture and education. Dr. Wu was Web Manager, Sr. Consultant, Sr. System Designer, Sr. System Architect, and Vice-President at Cantel AT&T, Ontario Government, HP, Manulife, Telus Mobility, and Oxford College, respectively. Dr. Wu is also the Chairman, Board of Directors of Chinese Information Technology Professionals Association of Canada.

Dr. Yali Wang (yali.wang@ccbpa.com)

Dr. Wang got his PhD degree from Shanghai Institute of Organic Chemistry, Chinese Academy of Science in 1988 in the field of protein and peptide Chemistry. He worked  as Postdoctoral Fellow in Physiologisch-chemisches Institut der Universitaet Tuebingen, Germany, and Institute for Biomedical Research of the University of Texas at Austin, USA, also served as Senior Scientist in Bio-synthesis Inc., Lewisville, Texas, and Multiple Peptide Systems Inc., San Diego, California before he joined Adherex Technologies Inc., Ottawa, as a project leader in 2000. After gaining more than 15 years of R&D experience in pharmaceutical industry, he started his own company - Advanced Syntech Corporation, Markham, Ontario, Canada in 2002. He published more than 20 papers in the field of protein and peptide chemistry and biochemistry, and was awarded the Max-Planck Fellowship for excellent young scientist from Max-Planck Foundation, Germany.

Dr. Yan Pan (yan.pan@ccbpa.com)

Dr. Pan received his Medical degree from Tianjin Medical University in 1985. He obtained his Ph.D. in Biochemistry from Osaka University in 1999. He completed his postdoctoral training at the Banting and Best Department of Medical Research, University of Toronto in 2002. Dr. Pan then joined the MDS-Protana where he was a project leader for a new service establishment - reverse chemical proteomics in drug discovery. He directed and implemented this service for Cephalon Inc, Alcon Laboratories Inc. and Synta Pharmaceuticals Corp, which resulted in the developing several extended applications of drugs. In 2005, he moved to Transition Therapeutics Inc. where he initiated a versican program, which resulted in the discovery and development of a lead candidate for cardiovascular diseases. Recently he has been collaborating with Eli Lilly and Elan Pharma International in the developing peptide-based drugs for large disease indications such as diabetes and Alzheimer’s disease. Dr. Pan also has served as an overseas expert on the grant review panel of the National Natural Sciences Foundation of China.

Dr. Jianying (Meg) Gao (jianying.gao@ccbpa.com)

Dr Gao received her BSc and MSc of Chemical Engineering from DaLian University of Technology in China. She obtained her PhD in Chemical Engineering in 2004 from University of Waterloo, CA. She worked as a Postdoctoral fellow on a joint project between University of Waterloo and sanofi pasteur in the field of metabolic flux modeling of mAb production processes. Since 2006, she has been working as a Development Scientist in Process Development at sanofi pasteur. She is working on vaccine development on different human diseases, such as invasive pneumococcal infection, tuberculosis, Herpes Simplex Virus, Chlamydia infection, and etc. In her current role, she is also responsible for SCADA system set up, design and validation, facility and equipment management and new technology evaluation.

Dr. Hongbo Yuan (hongbo.yuan@ccbpa.com)

Dr. Yuan received his MD degree from Tongji Medical University in 1988 and his Master of Science degree from Beijing Medical University in 1993. From 1993-1998, Dr. Yuan was an assistant professor at Beijing Medical University and a group leader in the China-US international collaborative project on the study of neural tube defects (NTDs)-a large intervention trial involving about 30 hospitals in Beijing and Shanghai areas. Dr. Yuan received an 'Outstanding Teacher Award' from Beijing Medical University in 1994. He earned his Ph.D. from McGill University Faculty of Medicine in 2003. This provided him advanced training in pharmacoepidemiology, clinical trial design and quantitative analysis. Dr Yuan joined the pharmaceutical industry in 2006 as a research consultant, Eli Lilly & Company, Indianapolis, Indiana, US. and a senior research position at Bristol-Myers Squibb in New Jersey, US. Prior to joining pharmaceutical industry, during 2003 to 2006, Dr. Yuan had worked at Toronto Western Hospital, UHN in clinical research, evidence-based medicine with responsibilities including protocol development and operating of clinical trials. Dr. Yuan's expertise is in clinical trial design, phase I-IV, with good knowledge in ICH GCPs guidelines and practical experiences in FDA's NDA and BLA submissions with activities involved including clinical protocol development, CRFs, statistical data analysis and clinical study reports as well as manuscripts for publications.  

Ms. Wenli Zhao (wenli.zhao@ccbpa.com)

Ms. Zhao first started her experience in biotechnology at the Biotechnology Program, Beijing University.  After achieved her honored Bachelor degree, she came to Canada to continue with her education at the Master of Biotechnology program at the University of Toronto.  In year 2006, she moved on to complete her Master in Business Administration (MBA) degree at McMaster University.  In between her studies, Ms. Zhao attempted to get diversified experiences in biotechnology industry.  She conducted molecular biology research at the University of Toronto, worked in drug development department at NPS pharmaceuticals, had experience in regulatory affairs with GlaxoSmithKline, learned drug pricing and reimbursement issues at Eli Lilly Canada and performed policy research with BIOTECanada.   

Mr. Fan (Henry) Pan (fan.pan@ccbpa.com)

Mr. Pan joined Sanofi Pasteur on May 2010. Presently he is working in the Department of Information Solutions as I.S. LIMS Manager. He is responsible for planning, organizing, executing and evaluating operations of LIMS/IS systems for both of Sanofi Pasteur's North American sites.  Prior to Sanofi Pasteur, Mr. Pan had worked in Apotex, the largest Canadian pharmaceutical company as a LIMS Consultant for 7 years since Aug. 2003. Mr. Pan received his M. S. Degree in Bio-chemistry from Fujian Normal University in 1995 and B. S. Degree in Bio-chemistry and Microbiology from Anhui University in 1986.